MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, May 03, 2023 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”) announced that the Company will release its first quarter 2023 financial results before the markets open on Thursday, May 11, 2023.
Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results. To access the call, analysts and investors may utilize the following:
| Toll free (U.S.) | 1-833-630-1956 |
| International (U.S) | 1-412-317-1837 |
| Germany | 0800-6647650 |
| Israel | 1-80-9212373 |
| Access Code | Please reference the “ReWalk Robotics Ltd. Call” |
The conference call will be webcast live and the webcast can be accessed through a link on the Company’s website at rewalk.com in the "Investors" section, or through the following link: https://edge.media-server.com/mmc/p/q5f8ebjx. An archived webcast will also be available on the company's website.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. is a medical device company that designs, develops, and commercializes innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions. ReWalk’s mission is to fundamentally change the quality of life for these individuals through the creation and development of market leading technologies. Founded in 2001, ReWalk has operations in the United States, Israel, and Germany. For more information on the ReWalk systems, please visit rewalk.com.
ReWalk® and ReStore® are registered trademarks of ReWalk Robotics Ltd. in the United States and other jurisdictions.
| ReWalk Investor Contact: Mike Lawless Chief Financial Officer ReWalk Robotics Ltd. E: This email address is being protected from spambots. You need JavaScript enabled to view it. | ReWalk Media Relations: John Tomlin E: This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$1.80 |
| Daily Change: | -0.14 -7.22 |
| Daily Volume: | 60,156 |
| Market Cap: | US$15.790M |
November 12, 2024 October 24, 2024 September 24, 2024 September 04, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
